Related references
Note: Only part of the references are listed.Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer
Gillian Thomas et al.
GYNECOLOGIC ONCOLOGY (2008)
Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia
Charles L. Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study
Robert E. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Treatment options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions
Jean-Philippe Spano et al.
ONCOLOGIST (2008)
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology American Society of Clinical Oncology clinical practice guideline update
J. Douglas Rizzo et al.
BLOOD (2008)
Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia
James R. Wright et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Do erythropoietin receptors on cancer cells explain unexpected clinical findings?
Michael Henke et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Once-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study
Yasuo Morishima et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial
JH Savonije et al.
EUROPEAN JOURNAL OF CANCER (2005)
Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study
B Leyland-Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy:: randomised, double-blind, placebo-controlled trial
M Henke et al.
LANCET (2003)
Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies:: a randomized, double-blind, placebo-controlled study
M Hedenus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial
G Iconomou et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2003)
Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology
JD Rizzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The level of haemoglobin in anaemic cancer patients correlates positively with quality of life
M Lind et al.
BRITISH JOURNAL OF CANCER (2002)
Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial
TJ Littlewood et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing
JL Gabrilove et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
